Solara Active Pharma Sciences Limited — Q1FY27 earnings call summary

Filed 29 July 2026 · Official transcript

Capex INR55-60 Cr in FY27; focus on debottlenecking capacity with 20-30% volume increase
Q1 FY27 revenue INR384 Cr +20% y-y; EBITDA INR63.5 Cr +10% y-y; PAT INR16.3 Cr +55% y-y
Ibuprofen business EBITDA margin negative 12%, expected loss INR10-15 Cr per quarter
Net debt reduced by INR135 Cr (22%) to INR479 Cr; target sub INR450 Cr by Mar-27
Strategic review of ibuprofen business expected by H1 FY27; options being evaluated
Base business capacity utilization ~70%; Vizag facility mothballed pending strategic decisions
Management cautious on West Asia crisis impact; transparent pricing pass-through ongoing
Base business revenue INR307 Cr +24% y-y; EBITDA INR72 Cr +8% y-y; gross margin ~52-55%